Bolt raised a $93.5M Series C to develop its Immune-Stimulating Antibody Conjugate (ISAC) platform and lead asset in HER2-expressing cancers. @BoltBio

Investors include RA, Surveyor, Rock Springs, Samsara, $PFE Ventures, $NVO Holdings, Vivo &amp; Pivotal.

https://t.co/aCqoSk4M6m